Physician profile
Allan D Halbert
NPI 1245231182
$4,064.16
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $672 · 2021: $1,007 · 2022: $483 · 2023: $595 · 2024: $85.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $408.20 | 2019-2023 | |
| Abbvie INC. | $407.92 | 2021-2024 | |
| Lilly USA, LLC | $376.97 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $361.25 | 2019-2023 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.99 | 2019-2023 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $321.39 | 2020-2023 | Shingrix |
| Astrazeneca Pharmaceuticals LP | $279.93 | 2019-2021 | |
| Novo Nordisk INC | $247.70 | 2019-2023 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $170.48 | 2019-2022 | |
| Abbott Laboratories | $135.39 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $133.07 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $129.15 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $100.04 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $97.80 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $96.21 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.14 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.11 | 2019-2020 | |
| Daiichi Sankyo INC. | $53.27 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $33.69 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.28 | 2023 | Gvoke Hypopen |
| Amarin Pharma, INC. | $20.98 | 2019 | |
| Allergan, INC. | $18.70 | 2020 | |
| Circassia INC. | $16.78 | 2019 | |
| Almatica Pharma LLC | $14.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.54 | 2021 | |
| Ibsa Pharma INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Halbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.